SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Lorus Therapeutics LORFF LOR

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Rampant who wrote (54)2/19/2000 12:18:00 AM
From: dennis naughler  Read Replies (3) of 101
 
Speculation & then reality

Believe me man!!!I got burned badly in the past on similar biotech plays. Anybody who is betting on a positive preclinical results from Lorus will be very disappointed.
This worthless writeup from The Global&Mail is there for one reason to keep everyone speculating for a positive result announcement while big boys quietly unloading their shares.


The Globe and Mail reports in its Tuesday, Feb. 8, edition that Lorus Therapeutics gained 29 cents to $2.57 yesterday on the Toronto Stock Exchange. The Globe's Market Movers column reports that the Montreal-based company's NuChem Pharmaceuticals unit has determined that its key anticancer drug NC 381 has shown positive preclinical results in tests using mice with human tumour cells. More than 3.8 million shares changed hands yesterday, says The Globe.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext